Benchmarking CIN 3+ risk as the basis for incorporating HPV and pap cotesting into cervical screening and management guidelines

Journal of Lower Genital Tract Disease

Volumn 17, Issue 5 SUPPL.1, 2013, Pages

  Katki, Hormuzd A ^a   Schiffman, Mark ^a   Castle, Philip E ^b   Fetterman, Barbara ^c   Poitras, Nancy E ^c   Lorey, Thomas ^c   Cheung, Li C ^d   Raine Bennett, Tina ^e   Gage, Julia C ^a   Kinney, Walter K ^f  

^a NATIONAL CANCER INSTITUTE   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c Regional Laboratory   (United States)

^d INFORMATION MANAGEMENT SERVICES INC   (United States)

^e DIVISION OF RESEARCH   (United States)

^f KAISER PERMANENTE   (United States)

Author keywords

Cancer prevention; Cervical intraepithelial neoplasia (CIN); Human papillomavirus (HPV); Pap

Indexed keywords

ADULT; ARTICLE; ATYPICAL SQUAMOUS CELLS OF UNDETERMINED SIGNIFICANCE; CANCER RISK; CANCER SCREENING; COLPOSCOPY; FEMALE; FOLLOW UP; HUMAN; PAPANICOLAOU TEST; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; WART VIRUS;

ADULT; BENCHMARKING; CERVICAL INTRAEPITHELIAL NEOPLASIA; FEMALE; HUMANS; MASS SCREENING; MIDDLE AGED; PAPILLOMAVIRUS INFECTIONS; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS; VIROLOGY;

EID: 84876151418     PISSN: 10892591     EISSN: 15260976     Source Type: Journal    
DOI: 10.1097/LGT.0b013e318285423c     Document Type: Article

References (16)

1. Moyer VA. Screening for cervical cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2012;156: 880-91, W312.
2. Saslow D, Solomon D, Lawson HW, Killackey M, Kulasingam SL, Cain JM, et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. J Low Genit Tract Dis 2012;16: 175-204.
3. Castle PE, Sideri M, Jeronimo J, Solomon D, Schiffman M. Risk assessment to guide the prevention of cervical cancer. J Low Genit Tract Dis 2008;12: 1-7.
4. Katki HA,Wacholder S, Solomon D, Castle PE, Schiffman M. Risk estimation for the next generation of prevention programmes for cervical cancer. Lancet Oncol 2009;10: 1022-3.
5. Katki HA, Kinney WK, Fetterman B, Lorey T, Poitras NE, Cheung L, et al. Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice. Lancet Oncol 2011;12: 663-72.
6. Solomon D, Davey D, Kurman R, Moriarty A, O'Connor D, Prey M, et al. The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA 2002;287: 2114-9.
7. Stoler MH, Schiffman M. Interobserver reproducibility of cervical cytologic and histologic interpretations: realistic estimates from the ASC-US-LSILTriage Study. JAMA 2001; 285: 1500-5.
8. Castle PE, Stoler MH, Solomon D, Schiffman M. The relationship of community biopsy-diagnosed cervical intraepithelial neoplasia grade 2 to the quality control pathologyreviewed diagnoses: an ALTS report. Am J Clin Pathol 2007; 127: 805-15.
9. Castle PE, Schiffman M, Wheeler CM, Solomon D. Evidence for frequent regression of cervical intraepithelial neoplasia-grade 2. Obstet Gynecol 2009;113: 18-25.
10. Moscicki AB, Ma Y, Wibbelsman C, Darragh TM, Powers A, Farhat S, et al. Rate of and risks for regression of cervical intraepithelial neoplasia 2 in adolescents and young women. Obstet Gynecol 2010;116: 1373-80.
11. Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S. Human papillomavirus and cervical cancer. Lancet 2007;370: 890-907.
12. Darragh TM, Colgan TJ, Cox JT, Heller DS, Henry MR, Luff RD, et al. The Lower Anogenital Squamous Terminology Standardization Project for HPV-Associated Lesions: Background and Consensus Recommendations From the College of American Pathologists and the American Society for Colposcopy and Cervical Pathology. J Low Genit Tract Dis 2012;16: 205-42.
13. Lawless JF. Statistical Models and Methods for Lifetime Data. 2nd ed. Hoboken, NJ: Wiley-Interscience; 2003.
14. Turnbull B. The empirical distribution function with arbitrarily grouped, censored and truncated data. J Roy Stat Soc B 1976;38: 290-5.
15. Katki HA, SchiffmanM, Castle PE, Fetterman B, Poitras NE, Lorey T, Cheung LC, et al. Five-year risk of CIN3+ to guide the management of women aged 21 to 24 years. J Lower Genit Tract Dis 2013;17:S64YS68.
16. Wang SS, Walker JL, Schiffman M, Solomon D. Evaluating the risk of cervical precancer with a combination of cytologic, virologic, and visual methods. Cancer Epidemiol Biomarkers Prev 2005;14(11 Pt 1): 2665-8.